Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Out-licensing

HESylation

Coupling drug substances with hydroxyethyl starch (HES) derivatives to improve pharmacokinetics and pharmacodynamics.

Mechanism of action

Coupling drug substances with hydroxyethyl starch (HES) derivatives.

Full description

HESylation is an innovative technology based on the extensive expertise of Fresenius Kabi in the field of hydroxyethyl starch (HES), the world's largest producer of HES. HES is a modified natural polymer that has been widely used in clinical practice for decades as a plasma volume expander. Consequently, it has an impressive safety record.

HESylation represents the technology of coupling drug substances with HES derivatives in order to modify drug characteristics, such as pharmacokinetics or water solubility. This also includes the prolongation of protein plasma circulation via an increased stability of the molecule and a reduced renal clearance, resulting in an increased biological activity. In addition, the immunogenicity or allergenicity might be reduced. By varying different parameters, such as the molecular weight of HES, a wide range of HES conjugates can be customized.

At present, the most important application area for HESylation is clearly biopharmaceuticals, i.e. protein drugs. Nevertheless, there is a strong potential for HESylation to improve the profile of small molecule drugs.

Development status

Preclinical

Patent information

Fresenius Kabi has a broad portfolio of patents and patent applications covering coupling chemistry, special linkers and HESylated substances on a target-by-target basis. Detailed information available on request.

Type of business relationship sought

Fresenius Kabi offers different kinds of partnerships including a specific technology transfer and supply of HES derivatives (one-stop-shop):

- Feasibility studies to evaluate the technology with different targets.

- Development collaborations to improve the efficacy or safety profile of protein/peptide drugs as well as small molecule drugs.

- Exclusive licensing of the HESylation technology for certain targets.

- Supply of customized HES derivatives and HESylated targets.

Licensing contact

Frank Feller
Project Manager
Request more information

More information

For more information about the product please visit website.

Company details

Fresenius Kabi
Fresenius Kabi is Europe's leading company in the field of infusion and nutrition therapies for seriously-ill and chronically-ill patients.

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related items

Related categories

Partnering consultation free of charge
Pharmaceutical Strategic Alliances
Biotech Patents
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us